Merck Sharp + Dohme Corp.

Abbvie Inc.

Merck Sharpe & Dohme Corp.

Feng Dong

Yan Li

Pingyu Zhong

Rose M Cubbon

Laurence B Peterson

Kevin Caili Wang

Jon H Condra

Peter Peizhi Luo

Holly A Hammond

Jeffrey T Blue

Ayesha Sitlani

Shilpa Pandit

Joseph C Santoro

Denise K Nawrocki

Henryk Mach

Dana D Wood

Sonia M Gregory

Lorenzo Benatuil

Jijie Gu

Andrei Alexandrovich Golosov

Xinwei Wang

Weirong Wang

Mark Hsieh

Timothy McCabe

Heidi Pixley

Yan Ni

Laura Orsatti

Heidi Yoder

Peizhi (Peter) Luo

Chung-Ming Hsieh

Tariq Ghayur

Ravi Chari

Anca Clabbers

Liangjun Lu

Preethi Krishnan

Tatyana Dekhtyar

Jacqueline G Bixby

Renee Miller

Axel Hernandez, Jr

Lucia Eaton

Teresa (Iok-Chan) Ng

Federico Mensa

Gautam Sahu

Jing Min

Gopalakrishnan Parthasarathy

Diana Bowley

Noel Byrne

Stephen Soisson

Jun Lu

Sujata Sharma

Kevin Caili Wangr

Matthew Rieser

Timothy Mccabe

The present disclosure provides anti-&#x3b1;4&#x3b2;7 antibodies that bind human &#x3b1;4&#x3b2;7, their methods of making, and their uses to treat patients with HIV infection.

Anti-alpha-4-beta-7 antibodies

Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.

Antibodies against platelet-derived growth factor (PDGF)

The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

High-throughput antibody humanization

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1B20 PCSK9 antagonists

AX132 PCSK9 antagonists

AX1 PCSK9 antagonists

1D05 PCSK9 antagonists

Growing community of inventors

Lansdale, PA, United States of America

Feng Dong